Adri C. Voogd

Adri C. Voogd

Auto-generated profile, based on publicly available information

Adri C. Voogd

Department of Epidemiology, Maastricht University, Maastricht, The Netherlands

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
Laura BiganzoliLaura Biganzoli
Laura Biganzoli
HWHans Wildiers
Hans Wildiers
COCatherine Oakman
Catherine Oakman
LMLorenza Marotti
Lorenza Marotti
SLSibylle Loibl
Sibylle Loibl
RARiccardo Audisio
Riccardo Audisio

15 March 2001 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AVAdri C. Voogd
Adri C. Voogd
MNMaja Nielsen
Maja Nielsen
JPJohannes L. Peterse
Johannes L. Peterse
MBMogens Blichert-Toft
Mogens Blichert-Toft
HBHarry Bartelink
Harry Bartelink
TCTreatment Of Cancer
Treatment Of Cancer
PURPOSE: Risk factors for local and distant recurrence after breast-conserving therapy and mastectomy were compared to define guidelines for the decision making between both treatments. PATIENTS AND METHODS: The data of two randomized clinical trials for stage I and II breast cancer patients were pooled. The total number of patients in the study was 1,772, of whom 879 underwent breast conservation, and 893, modified radical mastectomy. Representative slides of the primary tumor were available for histopathologic review in 1,610 cases (91%). RESULTS: There were 79 patients with local recurrence after breast-conservation and 80 after mastectomy, the 10-year rates being 10% (95% confidence interval [CI], 8% to 13%) and 9% (95% CI, 7% to 12%), respectively. Age no more than 35 years (compared with age >60: hazard ratio [HR], 9.24; 95% CI, 3.74 to 22.81) and an extensive intraductal component (HR, 2.52; 95% CI, 1.26 to 5.00) were significantly associated with an increased risk of local recurrence after breast-conserving therapy. Vascular invasion was predictive of the risk of local recurrence, irrespective of the type of primary treatment (P < .01). Tumor size, nodal status, high histologic grade, and vascular invasion were all highly significant predictors of distant disease after breast-conserving therapy and mastectomy (P < .01). Age no more than 35 years and microscopic involvement of the excision margin were additional independent predictors of distant disease after breast-conserving therapy (P < .01). CONCLUSION: Age no more than 35 years and the presence of an extensive intraductal component are associated with an increased risk of local recurrence after breast-conserving therapy. Vascular invasion causes a higher risk of local recurrence after mastectomy as well as after breast-conserving therapy and should therefore not be used for deciding between the two treatments.

9 April 2008 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
HHHarriët C. Hafkamp
Harriët C. Hafkamp
JMJ.J. Manni
J.J. Manni
AHA. Haesevoets
A. Haesevoets
AVA.C. Voogd
A.C. Voogd
MSM. Schepers
M. Schepers
ESErnst‐Jan M. Speel
Ernst‐Jan M. Speel

9 October 2013 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
DLDorien J. A. Lobbezoo
Dorien J. A. Lobbezoo
RKRoel J. W. van Kampen
Roel J. W. van Kampen
AVAdri C. Voogd
Adri C. Voogd
MDM. Wouter Dercksen
M. Wouter Dercksen
FBFranchette van Den Berkmortel
Franchette van Den Berkmortel
VTVivianne Tjan-Heijnen
Vivianne Tjan-Heijnen

16 April 2015 in British Journal of Cancer
Verified
Journal Article
Open access
DLD J A Lobbezoo
D J A Lobbezoo
RKR J W van Kampen
R J W van Kampen
AVA C Voogd
A C Voogd
MDM W Dercksen
M W Dercksen
FBF van Den Berkmortel
F van Den Berkmortel
VTV C G Tjan-Heijnen
V C G Tjan-Heijnen
We aimed to determine the prognostic impact of time between primary breast cancer and diagnosis of distant metastasis (metastatic-free interval, MFI) on the survival of metastatic breast cancer patients. Consecutive patients diagnosed with metastatic breast cancer in 2007-2009 in eight hospitals in the Southeast of the Netherlands were included and categorised based on MFI. Survival curves were estimated using the Kaplan-Meier method. Cox proportional hazards model was used to determine the prognostic impact of de novo metastatic breast cancer vs recurrent metastatic breast cancer (MFI ⩽24 months and >24 months), adjusted for age, hormone receptor and HER2 status, initial site of metastasis and use of prior (neo)adjuvant systemic therapy. Eight hundred and fifteen patients were included and divided in three subgroups based on MFI; 154 patients with de novo metastatic breast cancer, 176 patients with MFI 24 months. Patients with de novo metastatic breast cancer had a prolonged survival compared with patients with recurrent metastatic breast cancer with MFI 24 months (median, 29.4 vs 27.9 months, P=0.73). Adjusting for other prognostic factors, patients with MFI 24 months with de novo metastatic breast cancer no significant difference in mortality risk was found. The association between MFI and survival was seen irrespective of use of (neo)adjuvant systemic therapy. Patients with de novo metastatic breast cancer had a significantly better outcome when compared with patients with MFI 24 months, patients with de novo metastatic breast cancer had similar outcome.

1 March 2005 in European Journal of Cancer
Verified
Journal Article
Closed access
WLW.J. Louwman
W.J. Louwman
MJM.L.G. Janssen-Heijnen
M.L.G. Janssen-Heijnen
SHS. Houterman
S. Houterman
AVA.C. Voogd
A.C. Voogd
MSM.J.C. van der Sangen
M.J.C. van der Sangen
JCJ.W.W. Coebergh
J.W.W. Coebergh